The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

European Journal of Heart Failure

Volumn 19, Issue 11, 2017, Pages 1361-1378

  van Bilsen, Marc ^a   Patel, Hitesh C ^b,c,d   Bauersachs, Johann ^e   Böhm, Michael ^f   Borggrefe, Martin ^g,h   Brutsaert, Dirk ⁱ   Coats, Andrew J S ^j,k   de Boer, Rudolf A ^l   de Keulenaer, Gilles W ⁱ   Filippatos, Gerasimos S ^m   Floras, John ⁿ   Grassi, Guido ^o,p   Jankowska, Ewa A ^q,r   Kornet, Lilian ^s   Lunde, Ida G ^t   Maack, Christoph ^f   Mahfoud, Felix ^f   Pollesello, Piero ^u   Ponikowski, Piotr ^q,r   Ruschitzka, Frank ^v   Sabbah, Hani N ^w   Schultz, Harold D ^x   Seferovic, Petar ^y   Slart, Riemer H J A ^l,z   Taggart, Peter ^aa   Tocchetti, Carlo G ^ab   Van Laake, Linda W ^ac   Zannad, Faiez ^ad,ae   Heymans, Stephane ^af,ag   Lyon, Alexander R ^b,c   more..

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f Clinic for Internal Medicine III   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j MONASH UNIVERSITY   (Australia)

^k UNIVERSITY OF WARWICK   (United Kingdom)

^l UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^m UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁿ UNIVERSITY HEALTH NETWORK   (Canada)

^o UNIVERSITY OF MILANO BICOCCA   (Italy)

^p IRCCS MULTIMEDICA   (Italy)

^q WROCLAW MEDICAL UNIVERSITY   (Poland)

^r MILITARY HOSPITAL   (Poland)

^s MEDTRONIC BAKKEN RESEARCH CENTER   (Netherlands)

^t OSLO UNIVERSITY HOSPITAL   (Norway)

^u ORION CORPORATION   (Finland)

^v UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^w HENRY FORD HOSPITAL   (United States)

^x UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^y UNIVERSITY OF BELGRADE   (Serbia)

^z UNIVERSITY OF TWENTE   (Netherlands)

^aa UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ab UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^ac UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ad UNIVERSITY HOSPITAL OF NANCY   (France)

^ae UNIVERSITÉ DE LORRAINE   (France)

^af INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

^ag UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

Autonomic dysfunction; Devices and nerve ablation; Heart failure; Parasympathetic; Sympathetic

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; CAFFEINE; DIGITOXIN; DIGOXIN; DONEPEZIL; DONEPEZIL C 11; EPINEPHRINE C 11; GLYCERYL TRINITRATE; METHIODIDE QUINUCLIDINYL BENZILATE C 11; PHENYLEPHRINE; PHENYLEPHRINE C 11; PLACEBO; PYRIDOSTIGMINE; TRACER; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ALZHEIMER DISEASE; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; CHOLINERGIC SYSTEM; DEVICE THERAPY; DISEASE COURSE; DRUG TARGETING; ELECTROSTIMULATION; HEALTH CARE SYSTEM; HEART DISEASE; HEART FAILURE; HUMAN; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL; WORKSHOP; CARDIOLOGY; CONSENSUS; EUROPE; PATHOPHYSIOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH;

AUTONOMIC NERVOUS SYSTEM; CARDIOLOGY; CONSENSUS; EUROPE; HEART FAILURE; HUMANS; SOCIETIES, MEDICAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85030468745     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.921     Document Type: Article

References (145)

1. Floras JS, Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J 2015;36:1974–1982.
2. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819–823.
3. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998;351:478–484.
4. Galinier M, Pathak A, Fourcade J, Androdias C, Curnier D, Varnous S, Boveda S, Massabuau P, Fauvel M, Senard JM, Bounhoure JP. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur Heart J 2000;21:475–482.
5. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005;26:906–913.
6. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997;96:1173–1179.
7. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005;45:661–667.
8. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 2001;104:2194–2199.
9. Cohen-Solal A, Rouzet F, Berdeaux A, Le Guludec D, Abergel E, Syrota A, Merlet P. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med 2005;46:1796–1803.
10. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259–1265.
11. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, Dunselman PH, Boomsma F, Haaksma J, Lie KI. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group. J Am Coll Cardiol 1995;26:983–990.
12. Bohm M, Borer JS, Camm J, Ford I, Lloyd SM, Komajda M, Tavazzi L, Talajic M, Lainscak M, Reil JC, Ukena C, Swedberg K. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. Eur J Heart Fail 2015;17:518–526.
13. Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation 2003;108:266–269.
14. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.
15. Gorelik J, Wright PT, Lyon AR, Harding SE. Spatial control of the betaAR system in heart failure: the transverse tubule and beyond. Cardiovasc Res 2013;98:216–224.
16. El-Armouche A, Gocht F, Jaeckel E, Wittkopper K, Peeck M, Eschenhagen T. Long-term beta-adrenergic stimulation leads to downregulation of protein phosphatase inhibitor-1 in the heart. Eur J Heart Fail 2007;9:1077–1080.
17. Elsner D, Kromer EP, Riegger GA. Effects of vagal blockade on neurohumoral systems in conscious dogs with heart failure. J Cardiovasc Pharmacol 1990;15:586–591.
18. Schwartz PJ, Motolese M, Pollavini G, Lotto A, Ruberti UGO, Trazzi R, Bartorelli C, Zanchetti A; TISDP Group. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol 1992;3:2–16.
19. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 2007;13:178–184.
20. Binkley PF, Nunziatta E, Liu-Stratton Y, Cooke G. A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. Am Heart J 2005;149:342–348.
21. Patel HC, Rosen SD, Lindsay A, Hayward C, Lyon AR, di Mario C. Targeting the autonomic nervous system: measuring autonomic function and novel devices for heart failure management. Int J Cardiol 2013;170:107–117.
22. Bohm M, Reil JC. Heart rate: surrogate or target in the management of heart failure? Heart 2013;99:72–75.
23. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886–894.
24. Patel H, Ozdemir BA, Patel M, Xiao HB, Poole-Wilson PA, Rosen SD. Impairment of autonomic reactivity is a feature of heart failure whether or not the left ventricular ejection fraction is normal. Int J Cardiol 2011;151:34–39.
25. Magri D, Corra U, Di Lenarda A, Cattadori G, Maruotti A, Iorio A, Mezzani A, Giannuzzi P, Mantegazza V, Gondoni E, Sinagra G, Piepoli MF, Fiorentini C, Agostoni P. Cardiovascular mortality and chronotropic incompetence in systolic heart failure: the importance of a reappraisal of current cut-off criteria. Eur J Heart Fail 2014;16:201–209.
26. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996;17:354–381.
27. Notarius CF, Floras JS. Limitations of the use of spectral analysis of heart rate variability for the estimation of cardiac sympathetic activity in heart failure. Europace 2001;3:29–38.
28. Notarius CF, Butler GC, Ando S, Pollard MJ, Senn BL, Floras JS. Dissociation between microneurographic and heart rate variability estimates of sympathetic tone in normal subjects and patients with heart failure. Clin Sci (Lond) 1999;96:557–565.
29. La Rovere MT, Pinna GD, Raczak G. Baroreflex sensitivity: measurement and clinical implications. Ann Noninvasive Electrocardiol 2008;13:191–207.
30. Kornet L, Hoeks AP, Janssen BJ, Houben AJ, De Leeuw PW, Reneman RS. Neural activity of the cardiac baroreflex decreases with age in normotensive and hypertensive subjects. J Hypertens 2005;23:815–823.
31. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29:1147–1159.
32. Noordzij W, Slart RH. PET imaging of the autonomic myocardial function: methods and interpretation. Clin Transl Imaging 2015;3:365–372.
33. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141–149.
34. Mazzadi AN, Pineau J, Costes N, Le Bars D, Bonnefoi F, Croisille P, Porcher R, Chevalier P. Muscarinic receptor upregulation in patients with myocardial infarction: a new paradigm. Circ Cardiovasc Imaging 2009;2:365–372.
35. 11C]pyridostigmine and its analogs. Nucl Med Biol 2004;31:957–964.
36. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988;11:3–20.
37. Feng QP, Hedner T, Andersson B, Lundberg JM, Waagstein F. Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. Br Heart J 1994;71:261–267.
38. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001;49:27–37.
39. Robinson EA, Rhee KS, Doytchinova A, Kumar M, Shelton R, Jiang Z, Kamp NJ, Adams D, Wagner D, Shen C, Chen LS, Everett TH, Fishbein MC, Lin SF, Chen PS. Estimating sympathetic tone by recording subcutaneous nerve activity in ambulatory dogs. J Cardiovasc Electrophysiol 2015;26:70–78.
40. Vaseghi M, Lux RL, Mahajan A, Shivkumar K. Sympathetic stimulation increases dispersion of repolarization in humans with myocardial infarction. Am J Physiol Heart Circ Physiol 2012;302:H1838–H1846.
41. Rizas KD, Nieminen T, Barthel P, Zurn CS, Kahonen M, Viik J, Lehtimaki T, Nikus K, Eick C, Greiner TO, Wendel HP, Seizer P, Schreieck J, Gawaz M, Schmidt G, Bauer A. Sympathetic activity-associated periodic repolarization dynamics predict mortality following myocardial infarction. J Clin Investig 2014;124:1770–1780.
42. Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008;118:863–871.
43. Huang W, Shivkumar K, Vaseghi M. Device-based autonomic modulation in arrhythmia patients: the role of vagal nerve stimulation. Curr Treat Options Cardiovasc Med 2015;17:379.
44. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol 1995;268:R310–R316.
45. Sabbah HN, Ilsar I, Zaretsky A, Rastogi S, Wang M, Gupta RC. Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 2011;16:171–178.
46. Schwartz PJ, Pagani M, Lombardi F, Malliani A, Brown AM. A cardiocardiac sympathovagal reflex in the cat. Circ Res 1973;32:215–220.
47. Hamann JJ, Ruble SB, Stolen C, Wang M, Gupta RC, Rastogi S, Sabbah HN. Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. Eur J Heart Fail 2013;15:1319–1326.
48. Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, Van Wagoner DR, Mazgalev TN. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009;2:692–699.
49. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256–262.
50. Mortara A, La Rovere MT, Pinna GD, Prpa A, Maestri R, Febo O, Pozzoli M, Opasich C, Tavazzi L. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997;96:3450–3458.
51. Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, Camm AJ, Bigger JT Jr, Schomig A. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 1999;353:1390–1396.
52. Adamson PB, Smith AL, Abraham WT, Kleckner KJ, Stadler RW, Shih A, Rhodes MM. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004;110:2389–2394.
53. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011;32:847–855.
54. Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D'Onofrio A, Solomon SD, Wold N, Ruble SB. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015;36:425–433.
55. Premchand RK, Sharma K, Mittal S, Monteiro R, Dixit S, Libbus I, DiCarlo LA, Ardell JL, Rector TS, Amurthur B, KenKnight BH, Anand IS. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. J Card Fail 2014;20:808–816.
56. Libbus I, Nearing BD, Amurthur B, KenKnight BH, Verrier RL. Autonomic regulation therapy suppresses quantitative T-wave alternans and improves baroreflex sensitivity in patients with heart failure enrolled in the ANTHEM-HF study. Heart Rhythm 2016;13:721–728.
57. Gold MR, Van Veldhuisen DJ, Hauptman PJ, Borggrefe M, Kubo SH, Lieberman RA, Milasinovic G, Berman BJ, Djordjevic S, Neelagaru S, Schwartz PJ, Starling RC, Mann DL. Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF Trial. J Am Coll Cardiol 2016;68:149–158.
58. Bibevski S, Dunlap ME. Ganglionic mechanisms contribute to diminished vagal control in heart failure. Circulation 1999;99:2958–2963.
59. Bohm M, Ewen S, Kindermann I, Linz D, Ukena C, Mahfoud F. Renal denervation and heart failure. Eur J Heart Fail 2014;16:608–613.
60. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol 2014;64:635–643.
61. Tzafriri AR, Mahfoud F, Keating JH, Markham PM, Spognardi A, Wong G, Fuimaono K, Bohm M, Edelman ER. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol 2014;64:1079–1087.
62. Patel H, Dhillon P, Mahfoud F, Lindsay A, Hayward C, Ernst S, Lyon A, Rosen S, di Mario C. The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol 2014;103:337–344.
63. DiBona GF, Sawin LL. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol 1991;260:R298–R305.
64. Pettersson A, Hedner J, Hedner T. Renal interaction between sympathetic activity and ANP in rats with chronic ischaemic heart failure. Acta Physiol Scand 1989;135:487–492.
65. Hu J, Li Y, Cheng W, Yang Z, Wang F, Lv P, Niu C, Hou Y, Yan Y, Ge J. A comparison of the efficacy of surgical renal denervation and pharmacologic therapies in post-myocardial infarction heart failure. PLoS One 2014;9:e96996.
66. Dai Z, Yu S, Zhao Q, Meng Y, He H, Tang Y, Wang X, Xiao J, Huang C. Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model. EuroIntervention 2014;10:392–399.
67. Zhao Q, Yu S, Huang H, Tang Y, Xiao J, Dai Z, Wang X, Huang C. Effects of renal sympathetic denervation on the development of atrial fibrillation substrates in dogs with pacing-induced heart failure. Int J Cardiol 2013;168:1672–1673.
68. Patel HC, Hayward C, Vassiliou V, Patel K, Howard JP, Di Mario C. Renal denervation for the management of resistant hypertension. Integr Blood Press Control 2015;8:57–69.
69. Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903–1909.
70. Mahfoud F, Urban D, Teller D, Linz D, Stawowy P, Hassel JH, Fries P, Dreysse S, Wellnhofer E, Schneider G, Buecker A, Schneeweis C, Doltra A, Schlaich MP, Esler MD, Fleck E, Bohm M, Kelle S. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 2014;35:2224–2231.
71. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013;61:457–464.
72. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393–1401.
73. Patel HC, Hayward C, Ozdemir BA, Rosen SD, Krum H, Lyon AR, Francis DP, di Mario C. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension 2015;65:401–406.
74. Luscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J 2014;35:1706–1711.
75. Floras JS. Renal denervation for drug-resistant hypertension: suffering its original sin, seeking redemption. Can J Cardiol 2014;30:476–478.
76. Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Bohm M, Melder RJ. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 2015;66:1766–1775.
77. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, Hamady M, Hughes AD, Sever PS, Sobotka PA, Francis DP. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013;162:189–192.
78. Patel HC, Rosen SD, Hayward C, Vassiliou V, Smith GC, Wage RR, Bailey J, Rajani R, Lindsay AC, Pennell DJ, Underwood SR, Prasad SK, Mohiaddin R, Gibbs JS, Lyon AR, Di Mario C. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail 2016;18:703–712.
79. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012;59:901–909.
80. Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, Irwin ED, Serdar DJ, Peuler JD, Rossing MA. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007;50:904–910.
81. Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA, Kieval RS. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 2011;4:65–70.
82. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619–626.
83. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56:1254–1258.
84. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011;57:1787–1788.
85. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 2011;58:765–773.
86. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012;6:152–158.
87. Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A, Lovett EG, Mancia G, Grassi G. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014;16:977–983.
88. Gronda E, Seravalle G, Trevano FQ, Costantino G, Casini A, Alsheraei A, Lovett EG, Vanoli E, Mancia G, Grassi G. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction. J Hypertens 2015;33:1704–1708.
89. Abraham WT, Zile MR, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Muller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction. JACC Heart Fail 2015;3:487–496.
90. Zile MR, Abraham WT, Weaver FA, Butter C, Ducharme A, Halbach M, Klug D, Lovett EG, Muller-Ehmsen J, Schafer JE, Senni M, Swarup V, Wachter R, Little WC. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. Eur J Heart Fail 2015;17:1066–1074.
91. Prabhakar NR, Peng YJ. Peripheral chemoreceptors in health and disease. J Appl Physiol (1985) 2004;96:359–366.
92. Ding Y, Li YL, Schultz HD. Role of blood flow in carotid body chemoreflex function in heart failure. J Physiol 2011;589:245–258.
93. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997;95:1363–1365.
94. Ponikowski P, Chua TP, Anker SD, Francis DP, Doehner W, Banasiak W, Poole-Wilson PA, Piepoli MF, Coats AJS. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation 2001;104:544–549.
95. Imadojemu VA, Mawji Z, Kunselman A, Gray KS, Hogeman CS, Leuenberger UA. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest 2007;131:1406–1413.
96. Seals DR, Johnson DG, Fregosi RF. Hyperoxia lowers sympathetic activity at rest but not during exercise in humans. Am J Physiol 1991;260:R873–R878.
97. Olson LG, Hensley MJ, Saunders NA. Ventilatory responsiveness to hypercapnic hypoxia during dopamine infusion in humans. Am Rev Respir Dis 1982;126:783–787.
98. Del Rio R, Marcus NJ, Schultz HD. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J Am Coll Cardiol 2013;62:2422–2430.
99. Piccirillo G, Ogawa M, Song J, Chong VJ, Joung B, Han S, Magri D, Chen LS, Lin SF, Chen PS. Power spectral analysis of heart rate variability and autonomic nervous system activity measured directly in healthy dogs and dogs with tachycardia-induced heart failure. Heart Rhythm 2009;6:546–552.
100. Marcus NJ, Del Rio R, Schultz EP, Xia XH, Schultz HD. Carotid body denervation improves autonomic and cardiac function and attenuates disordered breathing in congestive heart failure. J Physiol 2014;592:391–408.
101. Chua TP, Ponikowski PP, Harrington D, Chambers J, Coats AJ. Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. Heart 1996;76:483–489.
102. Chua TP, Ponikowski P, Webb-Peploe K, Harrington D, Anker SD, Piepoli M, Coats AJ. Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur Heart J 1997;18:480–486.
103. Despas F, Lambert E, Vaccaro A, Labrunee M, Franchitto N, Lebrin M, Galinier M, Senard JM, Lambert G, Esler M, Pathak A. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Hypertens 2012;30:753–760.
104. Moore DP, Weston AR, Hughes JM, Oakley CM, Cleland JG. Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet 1992;339:850–853.
105. Vermeire P, de Backer W, van Maele R, Bal J, van Kerckhoven W. Carotid body resection in patients with severe chronic airflow limitation. Bull Eur Physiopathol Respir 1987;23 (Suppl 11):165–166.
106. Niewinski P, Janczak D, Rucinski A, Jazwiec P, Sobotka PA, Engelman ZJ, Fudim M, Tubek S, Jankowska EA, Banasiak W, Hart EC, Paton JF, Ponikowski P. Carotid body removal for treatment of chronic systolic heart failure. Int J Cardiol 2013;168:2506–2509.
107. Niewinski P, Janczak D, Rucinski A, Tubek S, Engelman ZJ, Piesiak P, Jazwiec P, Banasiak W, Fudim M, Sobotka PA, Javaheri S, Hart EC, Paton JF, Ponikowski P. Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study. Eur J Heart Fail 2017;19:391–400.
108. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009;373:82–93.
109. Yumino D, Kasai T, Kimmerly D, Amirthalingam V, Floras JS, Bradley TD. Differing effects of obstructive and central sleep apneas on stroke volume in patients with heart failure. Am J Respir Crit Care Med 2013;187:433–438.
110. Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. J Card Fail 2009;15:279–285.
111. Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, Parker JD, Bradley TD. Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. Heart 2009;95:819–824.
112. Prabhakar NR. Carotid body chemoreflex: a driver of autonomic abnormalities in sleep apnoea. Exp Physiol 2016;101:975–985.
113. Usui K, Bradley TD, Spaak J, Ryan CM, Kubo T, Kaneko Y, Floras JS. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol 2005;45:2008–2011.
114. Ruttanaumpawan P, Gilman MP, Usui K, Floras JS, Bradley TD. Sustained effect of continuous positive airway pressure on baroreflex sensitivity in congestive heart failure patients with obstructive sleep apnea. J Hypertens 2008;26:1163–1168.
115. Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003;348:1233–1241.
116. Gilman MP, Floras JS, Usui K, Kaneko Y, Leung RS, Bradley TD. Continuous positive airway pressure increases heart rate variability in heart failure patients with obstructive sleep apnoea. Clin Sci (Lond) 2008;114:243–249.
117. Hall AB, Ziadi MC, Leech JA, Chen SY, Burwash IG, Renaud J, deKemp RA, Haddad H, Mielniczuk LM, Yoshinaga K, Guo A, Chen L, Walter O, Garrard L, DaSilva JN, Floras JS, Beanlands RS. Effects of short-term continuous positive airway pressure on myocardial sympathetic nerve function and energetics in patients with heart failure and obstructive sleep apnea: a randomized study. Circulation 2014;130:892–901.
118. Lyons OD, Floras JS, Logan AG, Beanlands R, Cantolla JD, Fitzpatrick M, Fleetham J, John Kimoff R, Leung RS, Lorenzi Filho G, Mayer P, Mielniczuk L, Morrison DL, Ryan CM, Series F, Tomlinson GA, Woo A, Arzt M, Parthasarathy S, Redolfi S, Kasai T, Parati G, Delgado DH, Bradley TD. Design of the effect of adaptive servo-ventilation on survival and cardiovascular hospital admissions in patients with heart failure and sleep apnoea: the ADVENT-HF trial. Eur J Heart Fail 2017;19:579–587.
119. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095–1105.
120. Eulenburg C, Wegscheider K, Woehrle H, Angermann C, d'Ortho MP, Erdmann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H, Cowie MR. Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis. Lancet Respir Med 2016;4:873–881.
121. Jagielski D, Ponikowski P, Augostini R, Kolodziej A, Khayat R, Abraham WT. Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remede(R) System. Eur J Heart Fail 2016;18:1386–1393.
122. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, Abraham WT. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet 2016;388:974–982.
123. Lara A, Damasceno DD, Pires R, Gros R, Gomes ER, Gavioli M, Lima RF, Guimarães D, Lima P, Bueno CR, Vasconcelos A, Roman-Campos D, Menezes CAS, Sirvente RA, Salemi VM, Mady C, Caron MG, Ferreira AJ, Brum PC, Resende RR, Cruz JS, Gomez MV, Prado VF, de Almeida AP, Prado MAM, Guatimosim S. Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol Cell Biol 2010;30:1746–1756.
124. Azevedo ER, Parker JD. Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 1999;100:274–279.
125. Newton GE, Parker AB, Landzberg JS, Colucci WS, Parker JD. Muscarinic receptor modulation of basal and beta-adrenergic stimulated function of the failing human left ventricle. J Clin Investig 1996;98:2756–2763.
126. Sato K, Urbano R, Yu C, Yamasaki F, Sato T, Jordan J, Robertson D, Diedrich A. The effect of donepezil treatment on cardiovascular mortality. Clin Pharmacol Ther 2010;88:335–338.
127. Kubo T, Sato T, Noguchi T, Kitaoka H, Yamasaki F, Kamimura N, Shimodera S, Iiyama T, Kumagai N, Kakinuma Y, Diedrich A, Jordan J, Robertson D, Doi YL. Influences of donepezil on cardiovascular system – possible therapeutic benefits for heart failure-DOnepezil Cardiac TEst Registry (DOCTER) Study. J Cardiovasc Pharmacol 2012;60:310–314.
128. Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 2013;34:2585–2591.
129. Okazaki Y, Zheng C, Li M, Sugimachi M. Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure. J Physiol Sci 2010;60:67–74.
130. Li M, Zheng C, Kawada T, Inagaki M, Uemura K, Sugimachi M. Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. Eur J Heart Fail 2014;16:1056–1065.
131. Nobrega AC, dos Reis AF, Moraes RS, Bastos BG, Ferlin EL, Ribeiro JP. Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects. Clin Autonom Res 2001;11:11–17.
132. Behling A, Moraes RS, Rohde LE, Ferlin EL, Nóbrega ACL, Ribeiro JP. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. Am Heart J 2003;146:494–500.
133. Floras JS. Inhibitory effect of atrial natriuretic factor on sympathetic ganglionic neurotransmission in humans. Am J Physiol 1995;269:R406–R412.
134. Andersson U, Tracey KJ. Neural reflexes in inflammation and immunity. J Exp Med 2012;209:1057–1068.
135. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397–403.
136. Jagielska J, Salguero G, Schieffer B, Bavendiek U. Digitoxin elicits anti-inflammatory and vasoprotective properties in endothelial cells: therapeutic implications for the treatment of atherosclerosis? Atherosclerosis 2009;206:390–396.
137. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 1996;28:155–161.
138. Notarius CF, Morris B, Floras JS. Caffeine prolongs exercise duration in heart failure. J Card Fail 2006;12:220–226.
139. Haack KK, Zucker IH. Central mechanisms for exercise training-induced reduction in sympatho-excitation in chronic heart failure. Auton Neurosci 2015;188:44–50.
140. Corra U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, Lambrinou E, Pieske B, Piotrowicz E, Schmid JP, Seferovic PM, Anker SD, Filippatos G, Ponikowski PP. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failure association of the ESC. Eur J Heart Fail 2014;16:929–941.
141. Groehs RV, Toschi-Dias E, Antunes-Correa LM, Trevizan PF, Rondon MU, Oliveira P, Alves MJ, Almeida DR, Middlekauff HR, Negrao CE. Exercise training prevents the deterioration in the arterial baroreflex control of sympathetic nerve activity in chronic heart failure patients. Am J Physiol Heart Circ Physiol 2015;308:H1096–H1102.
142. Zannad F, Stough WG, Mahfoud F, Bakris GL, Kjeldsen SE, Kieval RS, Haller H, Yared N, De Ferrari GM, Pina IL, Stein K, Azizi M. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension 2015;65:5–15.
143. Smith S, Rossignol P, Willis S, Zannad F, Mentz R, Pocock S, Bisognano J, Nadim Y, Geller N, Ruble S, Linde C. Neural modulation for hypertension and heart failure. Int J Cardiol 2016;214:320–330.
144. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659–667.
145. Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert J-C, Holzmeister J, Lam CSP, Pochet T, Vincent A, Linde C. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. Eur J Heart Fail 2015;17:135–143.